

# Supporting Information

Clark et al. 10.1073/pnas.1114194108

## SI Materials and Methods

**Materials.** MRT67307 was synthesized by Natalia Shpiro in the Medical Research Council Protein Phosphorylation Unit. 5Z-7-oxozeaenol was purchased from BioAustralis Fine Chemicals. Pharmacological inhibitors were dissolved in DMSO and stored as 10 mM solutions at  $-20^{\circ}\text{C}$ . LTA, Pam<sub>3</sub>CSK<sub>4</sub>, poly(I:C), R837, and CpG-type B (ODN1826) were purchased from Invivogen and LPS (*Escherichia coli* strain O55:B5) was from Alexis Biochemicals. Mouse IL-1 $\alpha$  was purchased from Sigma-Aldrich. All antibodies used for immunoblotting and immunoprecipitation have been described previously with the exception of anti-IKK $\beta$  and anti-NEMO (1, 2). Antibodies were raised in sheep against the entire IKK $\beta$  (S189C, bleed 1) and NEMO (S190C, bleed 2) human proteins in sheep and affinity purified by the Division of Signal Transduction Therapy, University of Dundee.

**Mice.** MyD88<sup>-/-</sup>, TIR-domain-containing adapter-inducing IFN $\beta$  (TRIF)<sup>-/-</sup>, and TRAF associated NF $\kappa$ B activator (TANK)<sup>-/-</sup> mice were described previously (3–5). C57BL/6, MyD88<sup>-/-</sup>, and TRIF<sup>-/-</sup> mice were bred at the University of Dundee, whereas TANK<sup>-/-</sup> were bred at Osaka University under specific pathogen-free conditions in accordance with local regulations. C3H/HeJ mice were purchased from Charles River Laboratories. Work was approved by local ethical review and was performed with a UK Home Office project license.

**Cell Culture.** BMDMs were differentiated for 7 d in DMEM supplemented with 5 ng/mL recombinant M-CSF (R&D Systems) or 20% L929-conditioned medium as a source of M-CSF, 2 mM glutamine, 10% FCS, and the antibiotics penicillin and streptomycin. TBK1- and IKK $\epsilon$ -deficient mouse embryonic fibroblasts (MEFs) and control MEFs were cultured in DMEM supplemented with 10% FCS, 2 mM glutamine, penicillin, and streptomycin.


**Cell lysis and Immunoblotting.** Pharmacological inhibitors dissolved in DMSO, or an equivalent volume of DMSO for control incubations, were added to the culture medium of macrophages or fibroblasts. After 1 h at  $37^{\circ}\text{C}$ , the cells were stimulated with LTA, Pam<sub>3</sub>CSK<sub>4</sub>, poly(I:C), LPS, R837, CpG, or IL-1 $\alpha$  as described in the figure legends (Figs. 1–5 and Figs. S1–S4). Thereafter, the cells were rinsed in ice-cold PBS and extracted in lysis buffer (50 mM Tris/HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 5 mM sodium pyrophosphate, 10 mM sodium  $\beta$ -glycerol 1-phosphate, 1 mM DTT, 1 mM sodium orthovanadate, 0.27 M sucrose, 1% (vol/vol) Triton X-100, 1 mg/mL aprotinin, 1 mg/mL leupeptin, and 1 mM phenylmethylsulphonyl fluoride). Cell extracts were clarified by centrifugation at  $14,000 \times g$  for 10 min at  $4^{\circ}\text{C}$  and protein concentrations determined using the Bradford assay. To detect proteins in cell lysates, 20  $\mu\text{g}$  of protein extract was separated by SDS/PAGE. After transfer to PVDF membranes, proteins were detected by immunoblotting and visualized by treating the blots with ECL (Amersham) followed by autoradiography.

**Immunoprecipitation.** To immunoprecipitate endogenous TBK1, NEMO, and IKK $\beta$ , 1 mg of cell protein extract was incubated with 10  $\mu\text{g}$  of antibody for 2 h at  $4^{\circ}\text{C}$ , followed by the addition of Protein G Sepharose. After mixing for 30 min at  $4^{\circ}\text{C}$ , the immunocomplexes were washed three times in lysis buffer, denatured in SDS, and subjected to SDS/PAGE followed by immunoblotting.


**Statistical Analysis.** Data are presented as the mean  $\pm$  SEM. Statistical significance of differences between experimental groups was assessed using the Student *t* test and were considered significant if  $P < 0.05$ .

1. Clark K, Plater L, Pegg M, Cohen P (2009) Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and I $\kappa$ B kinase epsilon: A distinct upstream kinase mediates Ser-172 phosphorylation and activation. *J Biol Chem* 284:14136–14146.
2. Clark K, et al. (2011) Novel cross-talk within the IKK family controls innate immunity. *Biochem J* 434:93–104.


3. Adachi O, et al. (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. *Immunity* 9:143–150.
4. Yamamoto M, et al. (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. *Science* 301:640–643.
5. Kawagoe T, et al. (2009) TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. *Nat Immunol* 10:965–972.




**Fig. S1.** Activation of TBK1 and IKK $\epsilon$  by TLR ligands. (A) BMDMs were stimulated for 30 min without (–) or with (+) 100 ng/mL LPS and the cells lysed. TBK1 and IKK $\epsilon$  were immunoprecipitated separately from the cell extracts, washed and assayed for kinase activity without (–) or with (+) 1  $\mu$ M of MRT67307 or 1  $\mu$ M of the IKK $\beta$  inhibitor BI605906 as described under *Materials and Methods*. Reactions were terminated in SDS, the proteins resolved by SDS/PAGE, stained with Coomassie Blue (*Middle*), and the gels autoradiographed (*Top*). An aliquot of each immunoprecipitation was also immunoblotted for TBK1 and IKK $\epsilon$  as a loading control (*Bottom*). (B and C) BMDMs were stimulated for the times indicated with 2  $\mu$ g/mL LTA (B) or 2  $\mu$ g/mL R837 (C). The catalytic activities of TBK1 and IKK $\epsilon$  were then measured as described in A and quantitated by phosphorimager analysis (mean  $\pm$  SEM,  $n = 3$ ). Cell extract (20  $\mu$ g protein) was also immunoblotted with the antibodies indicated (bottom three panels).



**Fig. S2.** Effects of prolonged TLR signaling on the IKK-related kinases. (A) RAW264.7 cells were stimulated with 100 ng/mL LPS for the times indicated. TBK1 and IKK $\epsilon$  were immunoprecipitated and their catalytic activities were measured by incubating the immunoprecipitated kinases with GST-IRF3 and Mg[ $\gamma$ -<sup>32</sup>P]-ATP as described in *Materials and Methods* (*Upper*, second and third panels). Cell extract (20  $\mu$ g protein) was also immunoblotted with antibodies that recognize TBK1 phosphorylated at Ser172 to monitor activation by a second independent method (*Upper*). (*Lower* four panels) A total of 20  $\mu$ g cell extract protein was immunoblotted with the antibodies indicated. (B) RAW264.7 cells were stimulated for 16 h with 1  $\mu$ g/mL Pam<sub>3</sub>CSK<sub>4</sub>, 2  $\mu$ g/mL LTA, 10  $\mu$ g/mL poly(I:C), 100 ng/mL LPS, 2  $\mu$ g/mL R837, 1  $\mu$ g/mL CL097, or 2  $\mu$ M CpG. Cell extracts (20  $\mu$ g protein) were immunoblotted for IKK $\epsilon$  or TBK1 and for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a loading control.



**Fig. S3.** Activation of TBK1 and IKK $\epsilon$  in MyD88- and TRIF-deficient macrophages. BMDMs from MyD88 $^{-/-}$  or TRIF $^{-/-}$  mice or WT littermates were stimulated for the times indicated with (A) 1  $\mu$ g/mL Pam $_3$ CSK $_4$ , (B) 10  $\mu$ g/mL poly(I:C), (C) 2  $\mu$ g/mL R837, or (D) 2  $\mu$ M CpG. The catalytic activities of TBK1 and IKK $\epsilon$  were measured as described in Fig. S1 (top two panels) and *Materials and Methods*. Cell extracts (20  $\mu$ g protein) were also immunoblotted with the indicated antibodies (A, C, and D, bottom three panels and B, bottom four panels).



**Fig. S4.** Ablation of the IKK-related kinases enhances the IL-1–stimulated activation of the canonical IKKs in MEFs. Control and TBK1/IKK $\epsilon$  DKO MEFs were stimulated with 0.5 ng/mL (A) or 5 ng/mL (B) IL-1 $\alpha$  for the times indicated and the cell extracts were immunoblotted with the indicated antibodies. In B, note that the IL-1 $\alpha$ –stimulated decrease in the electrophoretic mobility of IKK $\beta$  was reduced in TBK1/IKK $\epsilon$  DKO MEFs (compare lanes 2–4 with 6–8).